in vivo News and Research

RSS

EPO grants patent to Rexahn’s new isoquinolinamine compounds for cancer

Rexahn Pharmaceuticals, Inc., a clinical stage pharmaceutical company commercializing potential best in class oncology and CNS therapeutics, today announced that the European Patent Office has granted European patent No. 2099765 to Rexahn, entitled "5, 6, or 7-Substituted-3-arylisoquinolinamine derivatives as antitumor agents."

27 Sep 2012

Advanced optics system noninvasively maps out network of tiny blood vessels beneath the skin

The trained eye of a dermatologist can identify many types of skin lesions, but human sight only goes so far. Now an international team of researchers has developed an advanced optics system to noninvasively map out the network of tiny blood vessels beneath the outer layer of patients' skin, potentially revealing telltale signs of disease.

24 Sep 2012

Bruker to purchase preclinical imaging product portfolio and related assets from Carestream

Carestream Health and Bruker have entered into an agreement for Bruker to purchase the preclinical in-vivo imaging equipment product portfolio and related assets from Carestream's Molecular Imaging business. Financial terms of the agreement are not being disclosed.

24 Sep 2012

PCA inhibits multiple pathways involved in development of diabetic nephropathy

Diabetic nephropathy is one of the most serious complications related to diabetes, often leading to end-stage kidney disease. Purple corn grown in Peru and Chile is a relative of blue corn, which is readily available in the U.S.

20 Sep 2012

vasopharm's explorative phase IIa NOSTRA trial in TBI meets clinical endpoints for safety

vasopharm GmbH, a pharmaceutical company dedicated to the discovery and development of novel therapeutics for the treatment of cerebro- and cardiovascular diseases, today announces that the explorative phase IIa NOSTRA trial in Traumatic Brain Injury Patients met all clinical endpoints for safety and in addition demonstrated strong evidence of clinical benefit in patients.

17 Sep 2012

Progenra’s P5091 inhibits growth of bortezomib resistant multiple myeloma tumor cells

Researchers at the Dana-Farber Cancer Institute and Progenra, Inc. announce the publication of a research article entitled "A Small Molecule Inhibitor of Ubiquitin-Specific Protease-7 Induces Apoptosis in Multiple Myeloma Cells and Overcomes Bortezomib Resistance."

17 Sep 2012

Solubilized curcumin shrinks lung tumors in mice

Belgian researchers report that orally administered curcumin can reduce the size of lung cancer tumors in mice.

13 Sep 2012

Researchers identify novel genes that make some children cope with malaria

Researchers from Sainte-Justine University Hospital Center and University of Montreal have identified several novel genes that make some children more efficient than others in the way their immune system responds to malaria infection.

12 Sep 2012

GE Healthcare announces data from [18F]flutemetamol phase III studies on Alzheimer's

GE Healthcare today announced pooled results from phase III brain autopsy and biopsy studies on the investigational PET amyloid imaging agent, [18F]flutemetamol, which showed a strong concordance between [18F]flutemetamol images and Alzheimer's disease-associated beta amyloid brain pathology.

11 Sep 2012

Islet Sciences licenses noninvasive technology from Winthrop for detecting Beta cell death

Islet Sciences, Inc., a biotechnology company engaged in the research, development and commercialization of patented technologies in the field of transplantation therapy for patients with diabetes, today announced that it has exclusively licensed technology from Winthrop University Hospital. This technology is complimentary to the early Beta cell destruction diagnostic that Islet Sciences licensed last month.

10 Sep 2012

Kalidex announces presentation of data on KPI-10 against MDR strains at ICAAC

Kalidex Pharmaceuticals, a privately-held anti-infective company, today announced the presentation of data on its lead development candidate KPI-10, a broad spectrum, next-generation fluoroquinolone, at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) in San Francisco, September 9 through 12.

7 Sep 2012

Researchers turn skin cells into embryonic Sertoli-like cells

Using a stepwise trans-differentiation process, Whitehead Institute researchers have turned skin cells into embryonic Sertoli-like cells.

7 Sep 2012

Phase 1b trial validates efficacy of Pulmatrix PUR118 to treat COPD

Pulmatrix, Inc., a clinical stage biotechnology company creating novel inhaled therapeutics, today announced top line results from a clinical study showing that the novel inhaled therapeutic, PUR118, demonstrated anti-inflammatory efficacy and was well-tolerated in two Phase 1b studies in patients with chronic obstructive pulmonary disease (COPD).

5 Sep 2012

IVIVC and Biowaivers in Drug Development 2012 seminar to take place in India

UBM Conferences brings to you the two-day conceptual seminar, IVIVC and Biowaivers 2012, taking place from October 30-31 in Mumbai, India.

3 Sep 2012

Glaucoma and cell death: an interview with Dr. Vivek Gupta

Glaucoma is normally caused by increased pressure of aqueous humour fluid in the eye. A defining feature of this disease is destruction of a particular type of cells in the retina called retinal ganglion cells and excavation of the optic disc region.

31 Aug 2012

Johns Hopkins team creates synthetic protein that can help locate tumors

Johns Hopkins researchers have created a synthetic protein that, when activated by ultraviolet light, can guide doctors to places within the body where cancer, arthritis and other serious medical disorders can be detected.

30 Aug 2012

Collegium commences enrollment in Oxycodone DETERx Phase 3 study in chronic lower back pain

Collegium Pharmaceutical, Inc., a specialty pharmaceutical company focused on the development of innovative treatments for chronic pain today announced that it has initiated enrollment in its Phase 3 clinical study for Oxycodone DETERx (COL-003).

30 Aug 2012

SPR microscopy examines binding kinetics of membrane proteins

Proteins adorning the surfaces of human cells perform an array of essential functions, including cell signaling, communication and the transport of vital substances into and out of cells. They are critical targets for drug delivery and many proteins are now being identified as disease biomarkers - early warning beacons announcing the pre-symptomatic presence of cancers and other diseases.

29 Aug 2012

Proteonomix enters license agreement for new anti-tumor technology

Proteonomix, Inc., a biotechnology company focused on developing therapeutics based upon the use of human cells and their derivatives, today announced that it has entered into an exclusive worldwide license agreement for a novel source of primary human cells that secrete a factor capable of inhibiting tumor cell growth and causing tumor cell death.

23 Aug 2012

Newly discovered on/off switch in enzymes may help battle fat-related disease

Enzymes involved in breaking down fat can now be manipulated to work three times harder by turning on a molecular switch recently observed by chemists at the University of Copenhagen. Being able to control this chemical on/off button could have massive implications for curing diseases related to obesity including diabetes, cardio vascular disease, stroke and even skin problems like acne. But the implications may be wider.

23 Aug 2012